Biosimilars Get Call-Out in PBMs’ 2nd Quarter Earnings Calls

Despite experiencing medical cost trends during the second quarter of 2021 that were much less favorable than they were a year ago, publicly traded health insurers during their recent earnings calls were eager to tout the performance of their pharmacy-related holdings. They placed particular emphasis on how integrated PBMs are poised to mine the cost-saving potential of biosimilar drugs.

“During the quarter, the strength of our Evernorth business was clearly a standout,” Cigna Corp. CEO David Cordani, for example, said during the company’s Aug. 5 conference call with investors to discuss quarterly financial results. Specifically, adjusted revenues for the segment — which includes the PBM Express Scripts — grew 14% year over year to $32.6 billion, and Evernorth’s pretax earnings grew 13% to $1.4 billion.

“Evernorth’s strong results in the quarter were driven by ongoing organic growth, driving both top and bottom line contributions, and continued progress on a range of affordability initiatives for the benefit of our customers and clients,” Chief Financial Officer Brian Evanko said. On the subject of affordability initiatives, Cordani singled out Cigna’s program that incentivizes patients to switch from branded immunosuppressive drug Remicade to various biosimilars.

© 2021 MMIT

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts
September 23

Experts: EU Will Continue to Beat US on Biosimilar Adoption

Read More
September 23

Pharma Industry Braces as Dems Hash Out Drug Price Package

Read More
September 23

Study Flags Potential Benefit of Targeted Medication Reviews

Read More


Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today